Regenerative Medicine Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

The regenerative medicine market was valued at US$ 11.77 billion in 2021 and is projected to reach US$ 37.48 billion by 2031; it is expected to grow at a CAGR of 17.9% from 2022 to 2031.

Regenerative medicine is an innovative field of medicine that develops methods for replacing/regenerating human cells, tissues, or organs to restore normal functions. It can heal tissues or organs by stimulating body's own repair mechanisms. Regenerative medicine allows scientists to grow tissues and organs in laboratory and safely implant them in the body when it cannot heal itself. 

Increasing adoption of gene therapies, stem cell therapies, and tissue engineering; growing number of approvals for cell and gene therapies; and technological advancements in the field of regenerative medicine are the key factors driving the market growth. However, the high cost of these therapies is hampering the market expansion.

The regenerative medicine market is analyzed on the basis of type, application, and geography. The report offers insights and in-depth analysis of the regenerative medicine market, emphasizing various parameters such as market trends, technological advancements, and market dynamics, as well as the competitive landscape analysis of leading market players.

Strategic Insights

Market Insights

Increasing Number of Cell and Gene Therapy Approvals Bolsters Regenerative Medicine Market Growth

Growing number of cell and gene therapies is likely to drive the market growth. For instance, in May 2022, the US Food and Drug Administration (FDA) approved Novartis Kymriah CAR-T cell therapy for adult patients with relapsed or refractory (r/r) follicular lymphoma (FL). Kymriah is the first approved CAR-T cell therapy developed together by Novartis and the Perelman School of Medicine at the University of Pennsylvania. In February 2022, Janssen Biotech, Inc received US FDA approval for its CARVYKTI (ciltacabtagene autoleucel; cilta-cel) to treat adults with relapsed or refractory multiple myeloma.

• In August 2022, Bluebird Bio, Inc. received US FDA approval for its Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy to treat adults and pediatric patients suffering from beta-thalassemia who require red blood cell transfusions regularly. 
• In March 2021, the US FDA approved Celgene Corporation’s Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to the treatment or whose disease has relapsed even after different types of therapies.

Type-Based Insights

Based on type, the regenerative medicine market is divided into cell-based immunotherapy and cell therapy products, tissue-engineered products, and gene therapy products. The cell-based immunotherapy and cell therapy products segment held the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.

Application-Based Insights

Based on application, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, and diabetes. The oncology segment occupied the largest market share in 2021 and is speculated to register the highest CAGR during 2022–2031.

The COVID-19 pandemic created growth opportunities for the market players due to the urgency of developing new therapies for COVID-19 patients. Several research projects were initiated in the cell and gene therapy research industry. For instance, in November 2021, Longeveron Inc. initiated its phase 1 trial to test the safety of Longeveron Mesenchymal Stem Cells (LMSCs) in adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19.

In 2022, North America held the largest share of the regenerative medicine market. The market growth is attributed to the rising research and development activities in the field of regenerative medicine. Asia Pacific is expected to register the fastest CAGR during the forecast period. China, Japan, and India are the major contributors to the regenerative medicine market in the region. The increasing stem cell research, rising government support for cell and gene research, and improvements in biotechnology infrastructure are the factors driving the market growth in APAC.

By geography, the regenerative medicine market is segmented into North America (The US, Canada, and Mexico), Europe (The UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (The UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Company Profiles

• Integra LifeSciences
• Gilead Sciences, Inc.
• Novartis AG 
• Vericel Corporation
• Wright Medical Group N.V.
• MiMedx Group
• Osiris Therapeutics, Inc.
• Stryker Corporation
• Spark Therapeutics, Inc.
• Medtronic plc

REGIONAL FRAMEWORK

Regenerative Medicine Market Report Analysis

MARKET PLAYERS

Regenerative Medicine Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.